Comprehensive liquid profiling of circulating tumor DNA and protein biomarkers in long-term follow-up patients with hepatocellular carcinoma - Details

author：

Indexed by：

Scopus

Abstract：

Purpose:　Circulating　tumor　DNA　(ctDNA)　provides　a　novel　approach　for　detecting　tumor　burden　and　predicting　clinical　outcomes　of　hepatocellular　carcinoma　(HCC).　Here,　we　performed　a　thorough　evaluation　of　HCC　circulating　genetic　features　and　further　fully　integrated　them　to　build　a　robust　strategy　for　HCC　monitoring　and　prognostic　outcome　assessment.　Experimental　Design:　We　performed　target　sequencing　and　low-coverage　whole-genome　sequencing　on　plasma　samples　collected　from　34　long-term　follow-up　patients　with　HCC　to　capture　tumor　somatic　SNVs　and　CNVs,　respectively.　Clinical　information　was　also　obtained　to　evaluate　the　prognostic　performance　of　ctDNA　comparing　with　clinically　applied　protein　biomarkers.　Results:　All　plasma　samples　before　surgery　showed　somatic　genetic　variations　resembling　corresponding　tumor　tissues.　During　follow-up,　SNVs　and　CNVs　dynamically　changed　correlating　to　patients＇　tumor　burden.　We　integrated　the　comprehensive　ctDNA　mutation　profiles　to　provide　a　robust　strategy　to　accurately　assess　patients＇　tumor　burden　with　high　consistence　comparing　with　imaging　results.　This　strategy　could　discover　tumor　occurrence　in　advance　of　imaging　for　an　average　of　4.6　months,　and　showed　superior　performance　than　serum　biomarkers　AFP,　AFP-L3%,　and　Des-Gamma-　Carboxy　Prothrombin　(DCP).　Furthermore,　our　strategy　could　precisely　detect　minimal　residual　disease　(MRD)　in　advance　and　predict　patients＇　prognostic　outcomes　for　both　relapsefree　survival　(P　=　0.001)　and　overall　survival　(P　=　0.001);　further　combining　ctDNA　with　DCP　could　increase　the　sensitivity　for　MRD　detection.　Conclusions:　We　demonstrated　that　plasma　CNV　and　SNV　levels　dynamically　correlated　with　patients＇　tumor　burden　in　HCC.　Our　strategy　of　comprehensive　mutation　profile　integration　could　accurately　and　better　evaluate　patients＇　prognostic　risk　and　detect　tumor　occurrence　in　advance　than　traditional　strategies.　©　2019　American　Association　for　Cancer　Research　Inc..　All　rights　reserved.

Keyword：

Community：

[ 1 ] [Cai, Z.]United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, 350025, China
[ 2 ] [Cai, Z.]Mengchao Med-X Center, Fuzhou University, Fuzhou, China
[ 3 ] [Cai, Z.]School of Life Science and Technology, Xi'An Jiaotong University, Xi'an, China
[ 4 ] [Cai, Z.]Liver Center of Fujian Province, Fujian Medical University, Fuzhou, China
[ 5 ] [Chen, G.]United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, 350025, China
[ 6 ] [Chen, G.]Mengchao Med-X Center, Fuzhou University, Fuzhou, China
[ 7 ] [Chen, G.]School of Life Science and Technology, Xi'An Jiaotong University, Xi'an, China
[ 8 ] [Chen, G.]Liver Center of Fujian Province, Fujian Medical University, Fuzhou, China
[ 9 ] [Zeng, Y.]United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, 350025, China
[ 10 ] [Zeng, Y.]Mengchao Med-X Center, Fuzhou University, Fuzhou, China
[ 11 ] [Zeng, Y.]Liver Center of Fujian Province, Fujian Medical University, Fuzhou, China
[ 12 ] [Zeng, Y.]Liver Disease Center, First Affiliated Hospital of Fujian Medical University, Fuzhou, China
[ 13 ] [Dong, X.]United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, 350025, China
[ 14 ] [Dong, X.]Mengchao Med-X Center, Fuzhou University, Fuzhou, China
[ 15 ] [Dong, X.]Liver Center of Fujian Province, Fujian Medical University, Fuzhou, China
[ 16 ] [Li, Z.]United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, 350025, China
[ 17 ] [Li, Z.]Mengchao Med-X Center, Fuzhou University, Fuzhou, China
[ 18 ] [Li, Z.]Liver Center of Fujian Province, Fujian Medical University, Fuzhou, China
[ 19 ] [Huang, Y.]United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, 350025, China
[ 20 ] [Huang, Y.]Liver Center of Fujian Province, Fujian Medical University, Fuzhou, China
[ 21 ] [Huang, Y.]Liver Disease Center, First Affiliated Hospital of Fujian Medical University, Fuzhou, China
[ 22 ] [Xin, F.]United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, 350025, China
[ 23 ] [Xin, F.]Liver Center of Fujian Province, Fujian Medical University, Fuzhou, China
[ 24 ] [Xin, F.]Liver Disease Center, First Affiliated Hospital of Fujian Medical University, Fuzhou, China
[ 25 ] [Qiu, L.]United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, 350025, China
[ 26 ] [Qiu, L.]Mengchao Med-X Center, Fuzhou University, Fuzhou, China
[ 27 ] [Qiu, L.]Liver Center of Fujian Province, Fujian Medical University, Fuzhou, China
[ 28 ] [Xu, H.]United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, 350025, China
[ 29 ] [Xu, H.]Mengchao Med-X Center, Fuzhou University, Fuzhou, China
[ 30 ] [Xu, H.]Liver Center of Fujian Province, Fujian Medical University, Fuzhou, China
[ 31 ] [Zhang, W.]Department of Respiratory and Critical Care Medicine, Changhai Hospital, Second Military Medical University, Shanghai, China
[ 32 ] [Su, X.]Children's Heart Center, Second Affiliated Hospital and Yuying Children's Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, China
[ 33 ] [Liu, X.]United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, 350025, China
[ 34 ] [Liu, X.]Mengchao Med-X Center, Fuzhou University, Fuzhou, China
[ 35 ] [Liu, X.]Liver Center of Fujian Province, Fujian Medical University, Fuzhou, China
[ 36 ] [Liu, J.]United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, 350025, China
[ 37 ] [Liu, J.]Mengchao Med-X Center, Fuzhou University, Fuzhou, China
[ 38 ] [Liu, J.]Liver Center of Fujian Province, Fujian Medical University, Fuzhou, China
[ 39 ] [Liu, J.]Liver Disease Center, First Affiliated Hospital of Fujian Medical University, Fuzhou, China

Reprint 's Address：

[Liu, X.]United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical UniversityChina

Email：

xiaoloong.liu@gmail.com

Show more details

Related Keywords：

Source ：

Clinical Cancer Research

ISSN： 1078-0432

Year： 2019

Issue： 17

Volume： 25

Page： 5284-5294

1 0 . 1 0 7

JCR@2019

1 0 . 4 0 0

JCR@2023

ESI HC Threshold：153

JCR Journal Grade：1

CAS Journal Grade：1

Cited Count：

WoS CC Cited Count： 0

SCOPUS Cited Count： 109

ESI Highly Cited Papers on the List： 0 Unfold All

WanFang Cited Count：

Chinese Cited Count：

30 Days PV： 2

Affiliated Colleges：

Get Fulltext

DOI Library Discovery Baidu Scholar Search SCOPUS

Type
Departments

All Years Choose Year From to